Administrative Core

行政核心

• 批准号: 7474413
• 负责人: Joel S. Bennett
• 金额: $ 7.02万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7474413
• 关键词: Administrator; Advisory Committees; Antibodies; Antibody Formation; Apple; Area; Biology; Blood Platelets; Budgets; Businesses; CXCR4 gene; Cardiovascular system; Charge; Complex; Computers; Cytoplasmic Tail; Electronic Mail; Endothelial Cells; Epitopes; Equipment and Supplies; Expenditure; F2R gene; Floor; Flow Cytometry; Funding; Future; Glycoproteins; Hematology; Human; Hybridomas; Individual; Manuscripts; Monitor; Monoclonal Antibodies; Mus; Numbers; PAC1 phosphatase; Participant; Pediatric Hospitals; Pennsylvania; Peptides; Photocopying; Platelet Glycoproteins; Price; Principal Investigator; Production; Recommendation; Research; Research Personnel; Services; Site; Specialist; System; Telephone; Thinking; Thrombin Receptor; Thrombosis; Universities; Visit; Wages; base; chemokine receptor; computerized; cost; day; discount; experience; interest; member; oncology; programs

The Administrative Core is essential for the conduct of this Program Project. It will continue to be based in the administrative area of the Hematology-Oncology Division at the University of Pennsylvania. The Core provides administrative support for the participants in the Program Project, as well as secretarial, and consultative functions and the supplies needed to support these functions. In addition, A. Administrative Functions To provide financial coordination for the Program Project, the Core Unit B leader and an experienced business administrator, Ms. Michele Arlotta, monitor the expenditures of each Project and Core Unit, facilitated by a system of computerized record keeping. Project leaders and Core Unit Leaders will be provided with monthly statements of the financial status of their projects or core units. Core Unit B will also serve to centralize the ordering of supplies and equipment, enabling the business administrator to monitor these expenditures and to take advantage of discounted prices available through the University. The business administrator will also oversee matters relating to the consortia with the Division of Hematology at the Children's Hospital of Pennsylvania and Thomas Jefferson University. B. Secretarial functions The Program Project will make use of 35% of the effort of a secretary, Mrs Terese Manganaro, who is based on the 9th floor of BRB 11/111 of the University of Pennsylvania. Mrs. Manganaro will type manuscripts and correspondence generated by the activities of the Program. She has an Apple Macintosh computer and is electronically networked to each investigator via the University of Pennsylvania E-mail network. C. Common Services and Supplies Core Unit B will provide the photocopying, postage, and telephone service needed to support the activities of the Program Project. D. Consultative functions Core Unit B will provide two types of consultative function. First, at monthly intervals, an outside investigator whose interests coincide with those of the members of the Program Project will be asked to a spend a day at the University, meet with the various Project leaders and Co-Investigators, and present a seminar at the weekly Thrombosis & Cardiovascular Biology Seminar. Funds required for these visitors in excess of those requested in the Core Unit Budget will be provided by other funds available to the Hematology-Oncology Division. Second, an External Advisory Committee composed of three members will be selected if and when the Program Project is re-funded. The Committee will be asked to visit the Program Project on a yearly basis, review its progress, and make specific recommendations regarding future directions. PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Page Continuation Format Page ,329 Principal Investigator/Program Director (Last, First, Middle): Bennett, Joel S. E. Continued Supply of Monoclonal Antibodies Since the inception of this Program Project, a Hybridoma Core (Core A), has produced a number of monoclonal antibodies (mAbs) to platelet and endothelial glycoproteins that have been highly useful to the Program. These include: A. Monoclonal antibodies to platelets glycoproteins allbfJS. Multiple antibodies have been produced by the Core to platelet allbbS and continue to be extensively utilized. These include mAbs specific for allb; (33; the allb(33 complex; activation-specific epitopes on the allb(33 complex; antiidiotypic mAbs to the activation-specific, anti allbps mAb PAC-1; and the cytoplasmic domains of allb and (33. B. Monoclonal antibodies to the human thrombin receptor (PAR1). The Core has had a particularly productive track-record in producing mAbs to epitopes on amino terminus of human PAR1 that have been useful in studies of platelets and endothelial cells. C. Monoclonal antibodies to the human PAR2. Antibodies to the PAR2 amino terminus (SAM11 and SAM12) have also been generated from mice immunized with the peptide, SLIGKVDGTSHVTG, corresponding to the first 14 residues of human PAR-2 starting at the activation site (Arg36-Ser37). The mAbs have been particularly useful for flow cytometry and immunohistochemical studies. D. Miscellaneous antibodies. Additional antibodies produced by the Core that have been used by Core members include mAbs to CD9 and the chemokine receptor CXCR4. At the renewal for Years 16-20, Core A was not recommended. However, because projects in the Program continued to use the mAbs listed above, funds were restored to enable continuing production of the antibodies. In this application, we have not proposed the production of new mAbs within the Program and have not requested continuation of Core A. But all of the project continue to make extensive use of one or more of these mAbs and therefore, we have requested modest partial salary support for a Research Specialist to produce them. Costs for supplies will be charged to individual projects as necessary. Although the Research Specialist does not perform an "administrative" function, she does perform a Program-wide function and we think Core B would be the most appropriate place to request support for her salary.

行政核心对于该计划项目的进行至关重要。它将继续 总部位于大学血液肿瘤学系的行政领域 宾夕法尼亚州。核心为计划项目的参与者提供管理支持， 以及秘书和咨询功能以及支持这些功能所需的供应。 此外， A.行政功能 为了为该计划项目提供财务协调，核心B单元领导者和经验丰富 商业管理员米歇尔·阿洛塔（Michele Arlotta）女士，监视每个项目和核心部门的支出， 由计算机记录保存系统促进。项目负责人和核心单位领导者将 提供有关其项目或核心单位财务状况的月度陈述。核心单元b 还将有助于集中供应和设备的顺序，使业务能够 管理员监视这些支出并利用可用的折现价格 通过大学。业务管理员还将监督与财团有关的事情 与宾夕法尼亚州儿童医院和托马斯·杰斐逊的血液学分裂 大学。 B.秘书功能 该计划项目将利用秘书Terese Manganaro夫人的35％ 基于宾夕法尼亚大学BRB 11/111的9楼。 Manganaro夫人将打字 该计划的活动产生的手稿和信件。她有一个苹果 MacIntosh计算机，并通过大学通过以电子方式网络 宾夕法尼亚州电子邮件网络。 C.普通服务和用品 核心单元B将提供支持支持的影印，邮费和电话服务 计划项目的活动。 D.协商功能 核心单元将提供两种类型的咨询功能。首先，按月间隔，外部 调查员的兴趣与计划项目成员的兴趣相吻合 在大学度过一天，与各种项目负责人和共同研究者会面， 在每周的血栓形成和心血管生物学研讨会上举行研讨会。所需的资金 这些访问者超过了核心单位预算中要求的访问者将由其他资金提供 可用于血液肿瘤科。第二，由外部咨询委员会组成 如果和何时重新资助了计划项目，则将选择三个成员。委员会将 被要求每年访问该计划项目，审查其进度并进行具体 有关未来方向的建议。 PHS 398/2590（修订版09/04，重新发行4/2006）页面延续格式页面 ，329 首席研究员/计划主任（最后，第一，中间）：贝内特，乔尔·S。 E.持续的单克隆抗体供应 自从该计划项目的成立以来，杂交瘤核心（核心A）已经产生了许多 对血小板和内皮糖蛋白的单克隆抗体（mAb），已经非常有用 到程序。其中包括： A.血小板糖蛋白AllBFJS的单克隆抗体。多种抗体已经 由核心到血小板Allbbs产生，并继续广泛使用。这些包括mab 特定于Allb； （33; allb（33络合物； AllB上的激活特异性表位（33络合物；抗iDiotiotypic 对激活特异性的抗Allbps mAb pac-1的mAb；和ALLB的细胞质结构域 和（33。 B.对人凝血酶受体的单克隆抗体（PAR1）。核心有一个 在人类PAR1的氨基末端产生mabs的MAB时，特别有生产力的曲目记录 在血小板和内皮细胞的研究中很有用。 C.人PAR2的单克隆抗体。 PAR2氨基末端的抗体（SAM11 和SAM12）也来自用肽Sligkvdgtshvtg免疫的小鼠产生 对应于从激活部位开始的人类PAR-2的前14个残基（ARG36-SER37）。 MAB对流式细胞仪和免疫组织化学研究特别有用。 D.其他抗体。由核心产生的其他抗体已使用 核心成员包括CD9的mAb和趋化因子受体CXCR4。 在续签16 - 20年的续约期间，不建议使用核心A。但是，因为 计划继续使用上面列出的单元子，恢复资金以启用继续 产生抗体。在此应用程序中，我们尚未提出生产新的mabs 在该计划中，没有要求继续进行CoreA。 广泛使用其中一个或多个mab，因此，我们要求谦虚 对研究专家的薪水支持来生产它们。物资的费用将被收取 必要的个别项目。尽管研究专家没有执行 “行政”功能，她确实执行了整个程序的功能，我们认为核心B将是 要求她的薪水支持的最合适的地方。